Biomarkers

Complex and uncommon EGFR Mutations in the Glans-Look database

Click on the drop-down buttons below for detailed treatment and survival information related to the following complex and uncommon EGFR mutations.

Complex EGFR mutations

Exon 19 del & L858R

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

Cytotoxic then TKI

Gefitinib

11.57

PD

9.29

16.50

TKI only

Gefitinib

14.51

Death

13.02

15.11

TKI only

Gefitinib

40.79

Patient decline

26.78

41.92

TKI only

Gefitinib

4.40

PD

1.65

6.21

TKI then cytotoxic

Gefitinib

16.03

PD

15.74

20.20

Exon 19 del & L858Q

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

TKI then cytotoxic

Gefitinib

8.56

PD

5.12

15.67

Exon 19 del, S768I, & V774M

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

TKI then cytotoxic

Gefitinib

19.44

PD

7.40

28.03

G719A & E709K

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

TKI only

Icotinib

9.49

PD

8.07

35.64

G719A & S768I

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

TKI only

Gefitinib

22.45

PD

22.18

22.73

G719X & Exon 19 del

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

TKI only

Gefitinib

2.61

AE

N/A

22.15

G719X & L861Q

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

No Tx

None

N/A

N/A

N/A

N/A

Cytotoxic then TKI

Erlotinib

7.67

Patient decline

3.70

7.67

G719X & S768I

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

TKI only

Gefitinib

8.56

PD

8.56

8.83

TKI only

Afatinib

56.10

N/A

N/A

53.09

TKI only

Gefitinib

2.15

PD

2.15

3.24

TKI only

Gefitinib

32.86

PD/T790M

29.29

45.82

TKI only

Gefitinib

0.93

Death

1.06

1.06

G719S & S768I

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

TKI only

Gefitinib

80.63

N/A

51.97

77.16

Uncommon EGFR mutations

Exon 20 Insertion

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

No Tx

None

N/A

N/A

N/A

N/A

No Tx

None

N/A

N/A

N/A

N/A

No Tx

None

N/A

N/A

N/A

N/A

Cytotoxic only

None

N/A

N/A

N/A

N/A

G719X

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

TKI then cytotoxic

Gefitinib

1.82

PD

1.62

9.19

TKI only

Gefitinib

14.35

PD

10.41

25.06

TKI only

Gefitinib

1.42

Patient decline

N/A

3.67

TKI only

Gefitinib

42.31

PD

20.76

45.42

TKI only

Afatinib

7.97

PD

4.56

12.79

TKI only

Gefitinib

0.99

Patient decline

N/A

45.16

Cytotoxic then TKI/ICI

Erlotinib

16.13

PD

10.91

17.65

L861Q

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

TKI only

Gefitinib

3.01

PD

3.01

5.26

TKI only

Gefitinib

1.62

Toxicity

N/A

17.62

TKI only

Gefitinib

14.35

PD

9.19

15.44

TKI only

Afatinib

11.34

PD

11.17

14.98

TKI then cytotoxic

Gefitinib

3.94

PD

3.27

4.43

TKI then cytotoxic

Gefitinib

4.40

PD

4.17

10.41

TKI only

Gefitinib

1.72

Death

N/A

1.72

TKI only

Gefitinib

7.07

Patient decline

N/A

9.36

TKI only

Gefitinib

2.81

PD

2.55

3.47

No Tx

None

N/A

N/A

N/A

N/A

TKI only

Afatinib

0.93

Toxicity

N/A

7.64

S768I

Treatment and Order

Initial TKI

Duration of TKI (months)

TKI End Reason

Progression Free Survival (months)

Survival Past TKI Start (months)

TKI only

Gefitinib

10.68

PD

10.48

13.26